Low dose long-acting factor VIII prophylaxis in pediatric and young adult patients with hemophilia A: Short-term single-center experience from a developing country
Open Access
- 29 August 2021
- journal article
- Published by Scientific Scholar in Journal of Hematology and Allied Sciences
- Vol. 1, 75-80
- https://doi.org/10.25259/jhas_13_2021
Abstract
Objectives: High dose factor prophylaxis in hemophilia has been proven to prevent joint bleeds in the western world effectively. We look for a cost-effective and feasible way for Indian patients to reduce the dose and frequency of factor infusion. Data on prophylaxis with a low dose, long-acting factor infusion twice a week dosing schedule is limited. The purpose was to study the efficacy and safety of long-acting factor VIII (Eloctate) for secondary/ tertiary prophylaxis in pediatric and young adult patients with moderate and severe hemophilia A. Materials and Methods: Thirty-eight patients with moderate and severe hemophilia A with an age range from 1 to 25 years were included in the study. During the initial 4 months, they received therapeutic doses of ELOCTATE (Factor VIII with Fc Fusion Protein) on an episodic basis after a clinical bleed. In the next 4 months, they received prophylactic intravenous ELOCTATE at the dose of 20 units/kg body weight twice a week. Annual bleeding rates (ABR), school absenteeism, emergency visits, joint scores, and adverse events were compared during both periods. Results: The total number of joint bleeds during the episodic treatment and prophylaxis period was 608 and 67, respectively. ABR was 47.9 during the episodic treatment period and 5.3 during prophylaxis showing an 88.9% reduction in joint bleeds. School/college absenteeism and emergency visits were significantly reduced during prophylaxis. No significant adverse events were noted during prophylaxis. Conclusion: Low dose, twice a week, and long-acting recombinant factor VIII-Fc (Eloctate) prophylaxis can be a reasonable options for patients with hemophilia A in developing countries.Keywords
This publication has 26 references indexed in Scilit:
- Hemophilia therapy: the future has begunHaematologica, 2020
- Is Low Dose a New Dose to Initiate Hemophilia A Prophylaxis? – A Systematic Study in Eastern IndiaIndian Journal of Pediatrics, 2020
- Establishing the Prevalence and Prevalence at Birth of Hemophilia in MalesAnnals of Internal Medicine, 2019
- Effect of tertiary prophylaxis with low-dose factor VIII in quality of life in adult patients with severe hemophilia AJournal of Applied Hematology, 2019
- Low‐dose prophylaxis for children with haemophilia in a resource‐limited setting in south India—A clinical audit reportHaemophilia, 2017
- A randomized study of very low‐dose factor VIII prophylaxis in severe haemophilia – A success story from a resource limited countryHaemophilia, 2016
- The past and future of haemophilia: diagnosis, treatments, and its complicationsThe Lancet, 2016
- A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)Journal of Thrombosis and Haemostasis, 2011
- Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in ChinaHaemophilia, 2010
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaThe New England Journal of Medicine, 2007